Tags

Type your tag names separated by a space and hit enter

Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children.
Vaccine. 2015 May 21; 33(22):2558-61.V

Abstract

BACKGROUND

Immunological studies have indicated that the effectiveness of AS03 adjuvanted monovalent influenza A(H1N1)pdm09 vaccine (Pandemrix) may be of longer duration than what is seen for non-adjuvanted seasonal influenza vaccines. Sixty-nine percent of children 6 months-18 years of age in Stockholm County received at least one dose of Pandemrix during the 2009 pandemic. We studied the effectiveness of the vaccine during the influenza seasons 2010-2011 and 2012-2013 in children hospitalized with virologically confirmed influenza. The season 2011-2012 was not included, since influenza A(H3N2) was the predominant circulating strain.

METHODS

In a retrospective case-control study using a modified test-negative design we compared the percentage vaccinated with Pandemrix among children diagnosed with influenza A(H1N1)pdm09 (cases), with that of those diagnosed with influenza A(H3N2) or influenza B (controls) during the two seasons. We excluded children born after July 1, 2009, since only children who were 6 months of age or older received the pandemic vaccine in October-December 2009.

RESULTS

During the 2010-2011 season, 3/16 (19%) of children diagnosed with influenza A(H1N1)pdm09, vs. 32/41 (78%) of those with influenza A(H3N2) or influenza B had been vaccinated with Pandemrix in 2009. The odds ratio, after adjustment for sex, age and underlying diseases, for becoming a case when vaccinated with Pandemrix was 0.083 (95%CI 0.014, 0.36), corresponding to a VE of 91.7%. During the season 2012-2013, there was no difference between the two groups; 59% of children diagnosed with influenza A(H3N2)/B and 60% of those with influenza A(H1N1)pdm09 had been vaccinated with Pandemrix in 2009.

CONCLUSION

The AS03 adjuvanted monovalent influenza A(H1N1) pdm09 vaccine (Pandemrix) was effective in preventing hospital admission for influenza A(H1N1)pdm09 in children during at least two seasons.

Authors+Show Affiliations

Karolinska Institutet, Department of Medicine, Unit of Infectious Diseases, Karolinska Solna, Stockholm, Sweden; Department of Communicable Disease Control and Prevention, Stockholm County Council, Box 175 33, SE-118 91 Stockholm, Sweden. Electronic address: ake.ortqvist@sll.se.Astrid Lindgren Children's Hospital, Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden.Astrid Lindgren Children's Hospital, Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden.Sachs' Children and Youth Hospital, Stockholm South General Hospital, Sjukhusbacken 10, SE-118 83 Stockholm, Sweden.Astrid Lindgren Children's Hospital, Karolinska University Hospital, Huddinge, SE-141 86 Stockholm, Sweden.Department of Communicable Disease Control and Prevention, Stockholm County Council, Box 175 33, SE-118 91 Stockholm, Sweden.Astrid Lindgren Children's Hospital, Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

25869891

Citation

Örtqvist, Åke, et al. "Long Term Effectiveness of Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Children." Vaccine, vol. 33, no. 22, 2015, pp. 2558-61.
Örtqvist Å, Bennet R, Hamrin J, et al. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children. Vaccine. 2015;33(22):2558-61.
Örtqvist, Å., Bennet, R., Hamrin, J., Rinder, M. R., Lindblad, H., Öhd, J. N., & Eriksson, M. (2015). Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children. Vaccine, 33(22), 2558-61. https://doi.org/10.1016/j.vaccine.2015.04.011
Örtqvist Å, et al. Long Term Effectiveness of Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Children. Vaccine. 2015 May 21;33(22):2558-61. PubMed PMID: 25869891.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children. AU - Örtqvist,Åke, AU - Bennet,Rutger, AU - Hamrin,Johan, AU - Rinder,Malin Ryd, AU - Lindblad,Hans, AU - Öhd,Joanna Nederby, AU - Eriksson,Margareta, Y1 - 2015/04/11/ PY - 2014/11/20/received PY - 2015/03/25/revised PY - 2015/04/02/accepted PY - 2015/4/15/entrez PY - 2015/4/15/pubmed PY - 2016/2/3/medline KW - Children KW - Effectiveness KW - Long term KW - Pandemic KW - Vaccination SP - 2558 EP - 61 JF - Vaccine JO - Vaccine VL - 33 IS - 22 N2 - BACKGROUND: Immunological studies have indicated that the effectiveness of AS03 adjuvanted monovalent influenza A(H1N1)pdm09 vaccine (Pandemrix) may be of longer duration than what is seen for non-adjuvanted seasonal influenza vaccines. Sixty-nine percent of children 6 months-18 years of age in Stockholm County received at least one dose of Pandemrix during the 2009 pandemic. We studied the effectiveness of the vaccine during the influenza seasons 2010-2011 and 2012-2013 in children hospitalized with virologically confirmed influenza. The season 2011-2012 was not included, since influenza A(H3N2) was the predominant circulating strain. METHODS: In a retrospective case-control study using a modified test-negative design we compared the percentage vaccinated with Pandemrix among children diagnosed with influenza A(H1N1)pdm09 (cases), with that of those diagnosed with influenza A(H3N2) or influenza B (controls) during the two seasons. We excluded children born after July 1, 2009, since only children who were 6 months of age or older received the pandemic vaccine in October-December 2009. RESULTS: During the 2010-2011 season, 3/16 (19%) of children diagnosed with influenza A(H1N1)pdm09, vs. 32/41 (78%) of those with influenza A(H3N2) or influenza B had been vaccinated with Pandemrix in 2009. The odds ratio, after adjustment for sex, age and underlying diseases, for becoming a case when vaccinated with Pandemrix was 0.083 (95%CI 0.014, 0.36), corresponding to a VE of 91.7%. During the season 2012-2013, there was no difference between the two groups; 59% of children diagnosed with influenza A(H3N2)/B and 60% of those with influenza A(H1N1)pdm09 had been vaccinated with Pandemrix in 2009. CONCLUSION: The AS03 adjuvanted monovalent influenza A(H1N1) pdm09 vaccine (Pandemrix) was effective in preventing hospital admission for influenza A(H1N1)pdm09 in children during at least two seasons. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/25869891/Long_term_effectiveness_of_adjuvanted_influenza_A_H1N1_pdm09_vaccine_in_children_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(15)00464-8 DB - PRIME DP - Unbound Medicine ER -